YM 46A

Drug Profile

YM 46A

Latest Information Update: 08 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antiasthmatics; Small molecules; Surfactants
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 14 May 1998 Phase-II clinical trials for Chronic obstructive pulmonary disease in European Union (PO)
  • 29 Apr 1997 Phase-I clinical trials for Chronic obstructive pulmonary disease in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top